文献速递泌尿与男性生殖病理

前列腺病理个体化报告:聚焦沟通与临床实用性

Personalized prostate pathology reporting: Focus on communication and clinical utility.
PubMed 文献 · Histopathology · 2026-01-01

该综述讨论当前前列腺癌病理报告在准确性、精确性、可重复性、标准化和完整性方面的问题,建议采用更简化的替代方法,聚焦病理数据的临床效用和有效沟通。前列腺癌的检测和管理原则与其他癌症显著不同,非靶向前列腺活检存在显著采样误差,阻碍准确判断肿瘤大小和分级;仅少数接受根治性前列腺切除术的患者可获得明确的肿瘤大小、分级和分期。血清标志物PSA的可用性也影响病理数据的临床效用,建议对前列腺活检报告采取务实方法,减少对肿瘤范围和分级精确测定的强调。

要点

  • 前列腺癌管理决策常基于非靶向活检病理,存在显著采样误差。
  • 仅少数根治性前列腺切除术患者可获得明确肿瘤大小、分级和分期。
  • 建议前列腺活检报告采取务实方法,减少对肿瘤范围和分级精确测定的强调。

核心结论

  • 建议对前列腺活检报告采取务实方法,减少对肿瘤范围和分级精确测定的强调,聚焦临床效用和有效沟通。

研究设计与样本

  • 综述,讨论前列腺癌病理报告实践的问题并提出简化替代方法。

主要发现

  • 前列腺癌检测和管理原则与其他癌症显著不同,对病理诊断和报告有重要影响。
  • 管理决策常基于非靶向前列腺活检病理数据,存在显著采样误差,阻碍准确判断肿瘤大小和分级。
  • 与其他实体瘤不同,仅少数接受根治性前列腺切除术的患者可获得明确的肿瘤大小、分级和分期。
  • 血清标志物PSA的可用性影响活检或前列腺切除标本病理数据的临床效用。

关键数值与推荐

  • 病理学家应报告所有强制数据项,但资源应聚焦于个体病例中有临床意义的数据。

临床怎么用

  • 前列腺活检报告采取务实方法,减少对肿瘤范围和分级精确测定的强调。
  • 病理学家应聚焦于个体病例中有临床意义的数据,并有效沟通病理信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Histopathology parameters are generally critical for the management of prostate cancer. Current practice is focussed on accuracy, precision, reproducibility, standardization and completeness of this data collection. This review discusses issues with this reporting practice and suggests a simpler alternative approach focussed on the clinical utility of pathology data and effective communication of the histopathology 'message'. The principles of prostate cancer detection and management are significantly different from those of other cancers. These differences could have important implications for the histopathological diagnosis and reporting of prostate cancer. Management decisions are often based on pathology data from nontargeted prostate biopsies that are subject to significant sampling error, which precludes accurate determination of tumour size and grade. In contrast to other solid tumours, definitive tumour size, grade, and stage are available only in the minority of patients who have undergone complete tumour excision (radical prostatectomy). The availability of a serum marker (prostate-specific antigen) for monitoring patients after prostate biopsy or prostatectomy would also significantly impact the clinical utility of histopathological data in these specimens. While it is necessary to report all mandatory data items, pathologists should focus their resources on data that are of clinical significance in an individual case. A pragmatic approach to prostate biopsy reporting with less emphasis on precise determination of tumour extent and grade is recommended.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Varma M, True LD. Personalized prostate pathology reporting: Focus on communication and clinical utility. Histopathology. 2026. PMID: 41384687. doi:10.1111/his.70000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。